Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Author： Westerhout Cynthia M   Boersma Eric  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.2, Iss.1, 2003-01, pp. : 49-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

By  

Heart Drug, Vol. 1, Iss. 2, 2004-11 ,pp. : 103-109

Karger

Access to resources Recommend Favorite

Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes

By Bosanquet N.  

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1135-1152

Adis International

Access to resources Recommend Favorite

Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1567-1570

Informa Healthcare

Access to resources Recommend Favorite

The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

By Manoharan G.   Maynard S.J.   Adgey A.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 555-566

Informa Healthcare

Access to resources Recommend Favorite

Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Segment Elevation Acute Coronary Syndromes: A Review and Guide to Patient Selection

By Atwater Brett D.   Roe Matthew T.   Mahaffey Kenneth W.  

Drugs, Vol. 65, Iss. 3, 2005-01 ,pp. : 313-324

Adis International

Access to resources Recommend Favorite